Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Immune checkpoint inhibitors have transformed cancer treatment by releasing T cell activity against tumors.
• However, many cancers exhibit resistance due to intrinsic or acquired mechanisms.
• Identifying tumor targets recognized by T cells, such as neoantigens, is crucial but not always feasible.

Purpose of the Study:

• To discuss the potential of epitope spreading in cancer therapy.
• To explore how T cells can be directed against non-mutated tumor antigens.
• To investigate strategies for inducing epitope spreading in neoantigen-deficient cancers.

Main Methods:

• Review and discussion of existing literature on immune checkpoint inhibitors and T cell responses.
• Analysis of the phenomenon of epitope spreading in high mutation contexts.
• Examination of recent evidence for exploiting epitope spreading in cancer treatment.

Main Results:

• Epitope spreading can lead to T cell responses against wild-type lineage proteins in high mutation settings.
• This mechanism may offer a therapeutic avenue for cancers with low neoantigen loads.
• Emerging evidence suggests purposeful induction of epitope spreading can achieve systemic tumor eradication.

Conclusions:

• Epitope spreading represents a promising mechanism to overcome resistance to current cancer immunotherapies.
• Targeting wild-type antigens via epitope spreading could broaden the applicability of T cell-based cancer treatments.
• Further research into inducing epitope spreading may lead to novel therapeutic strategies for diverse cancer types.